Abstract
Introduction: A prominent symptom of post-acute sequelae of SARS-CoV-2 infection (i.e., Long COVID) is exercise intolerance with or without post-exertional malaise (PEM). PEM is characterized by the worsening of both symptoms and function following even minor physical or mental exertion, with symptoms typically worsening 12 to 48 hours after activity and lasting for days or even weeks. Individualized, supervised cardiopulmonary rehabilitation is considered a safe and effective intervention for many cardiac and pulmonary conditions, and has been effective in gradually improving function in previously hospitalized and nonhospitalized patients with severe COVID-19. While traditional cardiopulmonary rehabilitation approaches appear helpful in some situations, the exercise intolerance symptoms experienced by many individuals with Long COVID may require a different approach, especially when attempts to increase physical activity result in PEM. No clear consensus exists on the optimal treatment of PEM, and no major studies have evaluated the efficacy in individuals with Long COVID of either carefully supervised, individualized cardiopulmonary rehabilitation programs for exercise intolerance without significant PEM or activity pacing interventions designed to treat or prevent PEM. Methods and Analysis: The Researching COVID to Enhance Recovery Clinical Trials (RECOVER-CT) initiative funded by the National Institutes of Health (NIH) included a prospective, multicenter, randomized controlled platform trial (RECOVER-ENERGIZE) designed to assess two interventions in patients with Long COVID and exercise intolerance: (1) cardiopulmonary rehabilitation for patients without significant PEM and (2) structured activity pacing to prevent or reduce PEM in participants who experience the symptom. The intervention duration will be 12 weeks. The primary endpoints for the trial include the Endurance Shuttle Walk Test as a measure of endurance capacity for the cardiopulmonary rehabilitation intervention and a modified version of the DePaul Symptom Questionnaire - Post-Exertional Malaise for the pacing intervention. Assessments will be completed at baseline, middle of intervention, end of intervention, and 12 weeks after completion of the intervention, and include physical performance measures and patient-reported surveys. Ethics and Dissemination: The RECOVER-ENERGIZE trial protocol has been approved by an institutional review board (Advarra), and written informed consent will be obtained from all participants prior to enrollment. The trial is registered on ClinicalTrials.gov (NCT06404047). Formally assessing PEM and developing a structured activity pacing intervention delivered by local pacing coaches are novel features of this trial. Results will be disseminated through peer-reviewed publications, presentations at scientific conferences, and communication with participants, patient advocacy organizations, and the broader Long COVID community. De-identified participant data will be made available through the NIH RECOVER data repository in accordance with NIH data-sharing policies. If successful, this protocol will provide accessible tools that clinicians can use to address exercise intolerance and PEM in patients with Long COVID.
Competing Interest Statement
Janna Friedly, MD, MPH: grant funding from Agency for Healthcare Research and Quality, Department of Defense, and National Institutes of Health. Lucinda Bateman, MD: principal investigator of REGAIN trial (NCT05840237) funded by Terra Biological LLC. G. Michael Felker, MD, MHS: research grants from National Institutes of Health, Bayer, BMS, Novartis, Merck, Cytokinetics, Otsuka, and CSL-Behring; he has acted as a consultant to Novartis, BMS, Cytokinetics, Boehringer-Ingelheim, Myovant, River2Renal, Roche Diagnostics, and Whiteswell, and has served on clinical endpoint committees/data safety monitoring boards for Merck, Rocket Pharma, and V-Wave. Steven J. Keteyian, PhD: Grant funding from National Heart, Lung, and Blood Institute; Scientific Advisory Board, Kento Health, Inc. Neil MacIntyre, MD: Consultant Inspirx Pharmaceuticals. Harry B. Rossiter, PhD: grants from National Institutes of Health (R01HL151452, R01HL166850, R01HL153460, P50HD098593, R01DK122767), Tobacco Related Disease Research Program (T31IP1666) and Department of Defense/U.S. Army Medical Research Acquisition Activity (HT9425-24-1-0249). Contracted clinical research with GlaxoSmithKline, Genentech, Intervene Immune, Mezzion, Regeneron, Respira, Roche and United Therapeutics. Pending patent application filed by The Lundquist Institute titled Testing System to Diagnose Neuromuscular Deconditioning and Pathologic Conditions. The remaining authors declare no potential conflicting interests.
Clinical Trial
NCT06404047
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Advarra gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
De-identified participant data will be made available through the NIH RECOVER data repository in accordance with NIH data-sharing policies.
Funder Information Declared
